PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31534544-0	2019	DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.	Sunitinib	40-49	glutaminyl-peptide cyclotransferase	Homo sapiens	26-30	
34036385-0	2021	QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis.	Sunitinib	33-42	glutaminyl-peptide cyclotransferase	Homo sapiens	0-4	
34036385-3	2021	It has previously been suggested that the protein glutaminyl-peptide cyclotransferase (QPCT) is closely related to sunitinib resistance in RCC.	Sunitinib	115-124	glutaminyl-peptide cyclotransferase	Homo sapiens	50-85	
34036385-3	2021	It has previously been suggested that the protein glutaminyl-peptide cyclotransferase (QPCT) is closely related to sunitinib resistance in RCC.	Sunitinib	115-124	glutaminyl-peptide cyclotransferase	Homo sapiens	87-91	
34036385-6	2021	On the whole, the data from the present study suggest that QPCT, CCCTC-binding factor (CTCF) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) may be used as targets for predicting, reversing and treating sunitinib-resistant RCC.	Sunitinib	239-248	glutaminyl-peptide cyclotransferase	Homo sapiens	59-63	
31534544-4	2019	We verified glutaminyl peptide cyclotransferase (QPCT) expression in sunitinib-nonresponsive and -responsive RCC tissues via qRT-PCR, western blot and immunohistochemical assays.	Sunitinib	69-78	glutaminyl-peptide cyclotransferase	Homo sapiens	12-47	
31534544-4	2019	We verified glutaminyl peptide cyclotransferase (QPCT) expression in sunitinib-nonresponsive and -responsive RCC tissues via qRT-PCR, western blot and immunohistochemical assays.	Sunitinib	69-78	glutaminyl-peptide cyclotransferase	Homo sapiens	49-53	
31534544-5	2019	Then, cell counting kit 8 (CCK-8), plate colony formation and flow cytometric assays were used to verify the function of QPCT in RCC sunitinib resistance after QPCT intervention or overexpression.	Sunitinib	133-142	glutaminyl-peptide cyclotransferase	Homo sapiens	121-125	
31534544-8	2019	Results: We found that the degree of methylation in the QPCT promoter region was significantly different between sunitinib-nonresponsive and -responsive RCC tissues.	Sunitinib	113-122	glutaminyl-peptide cyclotransferase	Homo sapiens	56-60	
31534544-9	2019	In the sunitinib-nonresponsive tissues, the degree of methylation in the QPCT promoter region was significantly reduced, and the expression of QPCT was upregulated, which correlated with a clinically poor response to sunitinib.	Sunitinib	7-16	glutaminyl-peptide cyclotransferase	Homo sapiens	73-77	
31534544-9	2019	In the sunitinib-nonresponsive tissues, the degree of methylation in the QPCT promoter region was significantly reduced, and the expression of QPCT was upregulated, which correlated with a clinically poor response to sunitinib.	Sunitinib	7-16	glutaminyl-peptide cyclotransferase	Homo sapiens	143-147	
31534544-9	2019	In the sunitinib-nonresponsive tissues, the degree of methylation in the QPCT promoter region was significantly reduced, and the expression of QPCT was upregulated, which correlated with a clinically poor response to sunitinib.	Sunitinib	217-226	glutaminyl-peptide cyclotransferase	Homo sapiens	143-147	
31534544-10	2019	A knockdown of QPCT conferred sunitinib sensitivity traits to RCC cells, whereas an overexpression of QPCT restored sunitinib resistance in RCC cells.	Sunitinib	116-125	glutaminyl-peptide cyclotransferase	Homo sapiens	102-106	
31534544-13	2019	Conclusion: QPCT may be a novel predictor of the response to sunitinib therapy in RCC patients and a potential therapeutic target.	Sunitinib	61-70	glutaminyl-peptide cyclotransferase	Homo sapiens	12-16